These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19758237)

  • 1. Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis.
    Giorgini A; Capsoni F; Podda M; Lleó A; Battezzati PM; Ongari AM; Selmi C; Benetti A; Malinverno F; Rossaro L; Gershwin ME; Zuin M
    Ann N Y Acad Sci; 2009 Sep; 1173():847-57. PubMed ID: 19758237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts.
    Durante-Mangoni E; Iardino P; Utili R; Adinolfi LE; Ruggiero G
    Antivir Ther; 2006; 11(5):637-40. PubMed ID: 16964833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.
    Tajuddin T; Ryan EJ; Norris S; Hegarty JE; O'Farrelly C
    J Gastroenterol Hepatol; 2010 Dec; 25(12):1883-90. PubMed ID: 21092001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
    Koirala J; Gandotra SD; Rao S; Sangwan G; Mushtaq A; Htwe TH; Adamski A; Blessman D; Khardori NM
    J Viral Hepat; 2007 Nov; 14(11):782-7. PubMed ID: 17927614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.
    Koskinas J; Zacharakis G; Sidiropoulos J; Elefsiniotis J; Savvas S; Kotsiou S; Kountouras D; Schina M; Kostopoulos P; Archimandritis A
    J Med Virol; 2009 May; 81(5):848-52. PubMed ID: 19319942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
    Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1192-9. PubMed ID: 21971375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil function and apoptosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.
    Jabłonowska E; Wójcik K; Kur B; Lewkowicz P; Nocuń M
    Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):61-8. PubMed ID: 22159474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.
    Striki A; Manolakopoulos S; Deutsch M; Mela M; Kalafateli M; Schini M; Anagnostou O; Triantos C; Andreadis I; Ketikoglou I; Papatheodoridis G; Pectasides D
    J Viral Hepat; 2014; 21(9):624-32. PubMed ID: 24224747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C.
    Liu YL; Du XF; Chen XY; Ma LN; Guo DD; Lu JF; Cao ZH; Zhang YH
    Scand J Infect Dis; 2013 Dec; 45(12):939-43. PubMed ID: 24090457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection.
    Juarez-Navarro A; Vera-de-León L; Navarro JM; Chirino-Sprung R; Díaz-Hernandez M; Casillas-Davila L; Dehesa-Violante M
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):317-22. PubMed ID: 16082419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study.
    Melia MT; Bräu N; Poordad F; Lawitz EJ; Shiffman ML; McHutchison JG; Muir AJ; Galler GW; Nyberg LM; Lee WM; Schiff E; Long J; Noviello S; Brass CA; Pedicone LD; Sulkowski MS
    Clin Infect Dis; 2014 Apr; 58(7):960-9. PubMed ID: 24399086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
    J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of biochemical safety between PEG-IFN alpha-2a and PEG-IFN alpha-2b.
    Katano Y; Kumada T; Nakano I; Toyoda H; Ishigami M; Hayashi K; Honda T; Goto H
    Hepatogastroenterology; 2009; 56(90):485-91. PubMed ID: 19579626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
    Cheong HR; Woo HY; Heo J; Yoon KT; Kim DU; Kim GH; Kang DH; Song GA; Cho M
    Korean J Hepatol; 2010 Mar; 16(1):38-48. PubMed ID: 20375641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
    Kang HM; Park MJ; Hwang JM; Kim JW; Jeong SH
    Korean J Hepatol; 2009 Jun; 15(2):209-15. PubMed ID: 19581773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.